Executive Director, GVAP HEOR Rare Tumors (all genders)

Work Your Magic with us!
Ready to explore, break barriers, and discover more? We know you’ve got big plans – so do we! Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Healthcare, Life Science, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and planet. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us.
United As One for Patients, our purpose in Healthcare is to help create, improve and prolong lives. We develop medicines, intelligent devices and innovative technologies in therapeutic areas such as Oncology, Neurology and Fertility. Our teams work together across 6 continents with passion and relentless curiosity in order to help patients at every stage of life. Joining our Healthcare team is becoming part of a diverse, inclusive and flexible working culture, presenting great opportunities for personal development and career advancement across the globe.
This position can be filled in Darmstadt, Germany or Boston, US.
Your role
You lead a team that develops and executes the global HEOR evidence generation and value demonstration strategy for the assets of the Rare Tumor Therapeutic Area across geographies. You provide scientific leadership, review, and management oversight of Rare Tumor global value demonstration initiatives, including HEOR studies and clinical trial support, Real World Data generation and Epidemiology, Patient Reported Outcomes and Quality of Life, and Comparative Effectiveness and Indirect Treatment Comparisons. You are accountable for the development and adaptation of the key health economic and value demonstration tools (economic models, dossiers, etc.) required for enabling early payer engagement, optimal pricing, and sustainable patient access. You work collaboratively with internal stakeholders (GVAP Brand Lead, R&D, Biostatistics, Epidemiology, Global medical affairs, global business franchise, policy and patient advocacy, etc.) and external partners (regulators, HTA agencies, healthcare decision makers, KOLs, academic partners) to support the creation of one integrated access strategy, aligning all related activities across development, launch, and life cycle management. You have strategic and leadership responsibilities by setting the evidence based comparative value strategy for all assets of the Rare Tumors Therapeutic Area and bringing a strong understanding of market access dynamics, reimbursement drivers, and barriers to ensure the Rare Tumors portfolio achieves optimal access and value realization.
Key tasks and responsibilities
You serve as the global Rare Tumors HEOR lead with full accountability for the development and communication of a clear value demonstration strategy for Rare Tumors assets, considering market dynamics.
You lead and develop a high performing team of Rare Tumors HEOR Strategy Leads and Scientific Directors, set directives, and coordinate regional and country HEOR colleagues.
You align HEOR strategies with brand strategy and contribute as needed to reimbursement and payer strategies; you clearly communicate HEOR strategies to the commercial team and train the commercial team as appropriate on HEOR data and the payer landscape.
You develop and oversee the Rare Tumors Value Demonstration Plan for the Therapeutic Area, including HTA readiness, RWE, PRO strategy, and health economic modeling, and ensure alignment with lifecycle plans and launch sequencing.
You are accountable for the GVAP Rare Tumors HEOR governance structures, including data standards and quality across all HEOR analyses, ensuring that activities comply with internal policies and external regulations; you institute risk assessment and define and track HEOR KPIs (e.g., time to HTA submission, completion rate of planned studies, and data quality measures).
You ensure the RT HEOR team functions in an integrated manner with key internal stakeholders in R&D, Biostatistics, Epidemiology, Global medical affairs, global business franchise, policy and patient advocacy, and with the GVAP Brand Lead to deliver results.
You establish and chair the Rare Tumors Value Assessment Strategy Team (VAST) to ensure cross functional governance, timely HTA deliverables, and payer facing inputs.
You represent and integrate the Global MAP perspective across governance bodies and cross functional platforms to secure and maintain access globally.
You cultivate relationships with payers, policymakers, academics, and patient advocates to strengthen the evidence base and maintain awareness of key industry developments across compassionate access, medical research, HTA, and the payer landscape.
You manage the Rare Tumors HEOR budget and acquire, allocate, and sustain the necessary resources (data assets, processes and procedures, and materials) to execute the evidence generation activities outlined above.
You set milestones and manage external vendors and external consultants to deliver timely, on budget, and high quality deliverables.
You mentor HEOR leadership and affiliates by recruiting, developing, and retaining a talented, high caliber team of individuals able to develop and execute the responsibilities listed above.
You perform other duties as assigned.
Who You Are
An advanced scientific degree such as a master's degree or doctorate in public health, health services research, health economics and outcomes research, epidemiology, statistics, economics, or a related field
At least 10 years of experience in health economics and outcomes research within the pharmaceutical or biotechnology industry, a market access function, a consultancy or a research institute.
At least 7 years of experience leading people, with responsibility for a global team, strategy, budgets, and resource allocation.
Deep expertise in economic modeling, evidence synthesis, patient reported outcomes, comparative effectiveness, real world evidence, and health technology assessment evidence packages.
Experience in rare diseases or oncology, including evidence generation and launch support across multiple geographies,